Razumilava N, Gores GJ (2013) Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol 11:e13–e14

Article  Google Scholar 

Huguet JM, Lobo M, Labrador JM et al (2019) Diagnostic-therapeutic management of bile duct cancer. World J Clin Cases 7:1732–1752

Article  PubMed  PubMed Central  Google Scholar 

Banales JM, Cardinale V, Carpino G et al (2016) Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 13:261–280

Article  PubMed  Google Scholar 

Khan SA, Davidson BR, Goldin RD et al (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update. Gut 61:1657–1669

Article  CAS  PubMed  Google Scholar 

Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281

Article  CAS  PubMed  Google Scholar 

Mizusawa J, Morizane C, Okusaka T et al (2016) Randomized phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan clinical oncology group study (JCOG1113, FUGA-BT). Jpn J Clin Oncol 46:385–388

Article  PubMed  PubMed Central  Google Scholar 

Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 30:1950–1958

Article  CAS  PubMed  Google Scholar 

Ioka T, Kanai M, Kobayashi S et al (2023) Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci 30:102–110

Article  PubMed  Google Scholar 

Cheng CY, Chen CP, Wu CE (2022) Precision medicine in cholangiocarcinoma: past, present, and future. Life 12:829

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciardiello D, Maiorano BA, Parente P et al (2022) Immunotherapy for biliary tract cancer in the era of precision medicine: current knowledge and future perspectives. Int J Mol Sci 23:820

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21:671–684

Article  CAS  PubMed  PubMed Central  Google Scholar 

Churi CR, Shro R, Wang Y et al (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 9:e115383

Article  PubMed  PubMed Central  Google Scholar 

Chakrabarti S, Kamgar M, Mahipal A (2020) Targeted therapies in advanced biliary tract cancer: an evolving paradigm. Cancers 12:2039

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rizzo A, Ricci AD, Brandi G et al (2021) Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun 27:100337

Article  PubMed  Google Scholar 

Lamarca A, Barriuso J, McNamara MG et al (2020) Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol 73:170–185

Article  CAS  PubMed  Google Scholar 

Goyal L, Meric-Bernstam F, Hollebecque A et al (2023) Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 388:228–239

Article  CAS  PubMed  Google Scholar 

Oh DY, He AR, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1(8):EVIDoa2200015

Article  PubMed  Google Scholar 

Rimini M, Fornaro L, Lonardi S et al (2023) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int 43:1803–1812

Article  CAS  PubMed  Google Scholar 

Zhao S, Zhang Z, Zhan J et al (2021) Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer. BMC Med 19(1):223

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pishvaian MJ, Blais EM, Brody JR et al (2020) Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol 21(4):508–518

Article  CAS  PubMed  PubMed Central  Google Scholar 

Israel MA, Danziger N, McGregor KA et al (2021) Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns. Oncologist 26:787–796

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ishido S, Tamaki N, Inada K et al (2023) Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test. Clin Case Rep 11:e7664

Article  PubMed  PubMed Central  Google Scholar 

Toshida K, Itoh S, Yugawa K et al (2023) Prognostic significance for recurrence of fibroblast growth factor receptor 2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection. Hepatol Res 53(5):432–439

Article  CAS  PubMed  Google Scholar 

Tsujie M, Iwai T, Kubo S et al (2021) Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma. Jpn J Clin Oncol 51(6):911–917

Article  PubMed  PubMed Central  Google Scholar 

Maruki Y, Morizane C, Arai Y et al (2021) Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study). J Gastroenterol 56(3):250–260

Article  CAS  PubMed  Google Scholar 

Takada K, Kubo T, Kikuchi J et al (2022) Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: a prospective multicenter study. Front Oncol 2(12):988527

Article  Google Scholar 

Zhang D, Dorman K, Heinrich K et al (2023) A retrospective analysis of biliary tract cancer patients presented to the molecular tumor board at the Comprehensive Cancer Center Munich. Target Oncol 18(5):767–776

Article  PubMed  PubMed Central  Google Scholar 

Milbury CA, Creeden J, Yip WK et al (2022) Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. PLoS One 17(3):e0264138

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woodhouse R, Li M, Hughes J et al (2020) Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One 15(9):e0237802

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato M, Nakamura H, Nagai M et al (2018) A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing. Genome Med 10(1):44

Article  PubMed  PubMed Central  Google Scholar 

Sunami K, Ichikawa H, Kubo T et al (2019) Feasibility and utility of a panel testing for 114 ca